Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04655976
Title	Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung)
Acronym	COSTAR Lung
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	GlaxoSmithKline
Indications	lung non-small cell carcinoma
Therapies	Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly Docetaxel + Dostarlimab-gxly
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS